Harrow Health, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
Bonitas Research released a report on February 22, 2023, which claimed that Harrow had kept quiet about a U.S. Department of Justice investigation into its sales practices and had engaged in questionable transactions with former subsidiaries. Additionally, Harrow had not revealed that it received a warning letter from the U.S. Food and Drug Administration for misleading marketing claims. However, months later, the company issued a recall across the country. As a result of this news, Harrow’s stock price dropped by 3.2%, or $0.54, to close at $16.42 on February 22, 2023, causing harm to investors.
